• 1
    Vergilio JA, Bagg A. Myelodysplastic syndromes: contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol 2003; 119( suppl 1): S58S77.
  • 2
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 20792088.
  • 3
    Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394403.
  • 4
    Stetler-Stevenson MA, Arthur D, Jabbour N, Xie XY, Molldrem J, Barrett AJ. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes. Blood 2001; 98: 979987.
  • 5
    Shichishima T, Shikama Y, Saitoh Y, Ogawa K, Maruyama Y. Neutrophil-specific reduction in the expression of granulocyte-macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. Exp Hematol 2002; 30: 187194.
  • 6
    Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 38873896.
  • 7
    Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 23492356.
  • 8
    Karmon Y, Manaster J, Chezar J. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis. Cytometry 2002; 50: 225230.
  • 9
    Chang CC, Cleveland R. Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. Arch Pathol Lab Med 2000; 124: 11521156.
  • 10
    Del Canizo MC, Fernandez M, Lopez A, Vidriales B, Villaron E, Arroyo JL, et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003; 88: 402407.
  • 11
    Shikama Y, Shichishima T, Ohto H, Jubinsky PT, Maruyama Y. Neutrophil-specific reduction in the expression of granulocyte-macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. Br J Haematol 2000; 111: 863872.
  • 12
    Inaba T, Shimazaki C, Sumikuma T, Shimura K, Takahashi R, Hirai H, et al. Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome. Int J Hematol 1998; 68: 403410.
  • 13
    Meletis J, Terpos E, Samarkos M, Meletis C, Konstantopoulos K, Komninaka V, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematologia (Budapest) 2001; 13: 716.
  • 14
    Kyriakou D, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Mavromanolakis M, et al. Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells. Int J Hematol 2001; 73: 483491.
  • 15
    Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 1997; 98: 108113.
  • 16
    Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol 1993; 84: 428435.
  • 17
    JaffeES, HarrisNL, SteinH, VardimanJW, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
  • 18
    Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003; 127: 11401147
  • 19
    Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 1993; 677: 265280.
  • 20
    Lanza F, Castagnari B, Rigolin G, Moretti S, Latorraca A, Ferrari L, et al. Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells. Leukemia 1997; 11: 17001710.
  • 21
    Skubitz KM, Campbell KD, Skubitz AP. Synthetic peptides from the N-domains of CEACAMs activate neutrophils. J Pept Res 2001; 58: 515526.
  • 22
    Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 39323938.
  • 23
    Cutrona G, Leanza N, Ulivi M, Melioli G, Burgio VL, Mazzarello G, et al. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood 1999; 94: 30673076.
  • 24
    Cutrona G, Tasso P, Dono M, Roncella S, Ulivi M, Carpaneto EM, et al. CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer 2002; 86: 17761785.
  • 25
    Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002; 26: 677686.
  • 26
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. Granulocyte-macrophage colony-stimulating factor: inhibitor of tumor necrosis factor-induced apoptosis. Leuk Res 2003; 27: 539545.